Submitted by Anonymous (not verified) on 19 October 2023 - 16:33
Human medicines European public assessment report (EPAR): Mavenclad, cladribine, Multiple Sclerosis, Date of authorisation: 22/08/2017, Revision: 9, Status: Authorised
Source: